Characterizing a drug candidate for Gq coupled GPCR
This Poster summarizes a study from the Actelion Drug Discovery Department, characterizing the inhibitory potency of the drug candidate macitentan on ETA and ETB4,5, two GPCRs involved in pulmonary arterial hypertension (PAH).
- Methodology followed by the authors
- Key results of the study (antagonist potency and binding kinetics)
- Conclusion suggesting the unique effectiveness of the macitentan compound